Drug Profile
Research programme: intron fusion proteins - Symphogen
Alternative Names: Dimercept; IFP/SCAN; Intron Fusion ProteinsLatest Information Update: 09 Jun 2020
Price :
$50
*
At a glance
- Originator Oregon Health & Science University; Receptor BioLogix
- Developer Symphogen
- Class
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation; Metabolic disorders
Most Recent Events
- 04 Jun 2020 Symphogen has been acquired by Servier
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA